BLFSNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
BIOLIFE SOLUTIONS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$38.61+0.00 (0.00%)
Close on Oct 7, 2026
- Market cap
- $1.90B
- P/E (TTM)
- 33.6
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
64.6%
Operating margin
-17.3%−4.3 pts over 5 years
Net margin
-4.8%−8.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +28.9% | +8.1% | +14.9% | +31.0% | |
| Gross profit | +24.0% | – | – | +32.2% | |
| Free cash flow | +104.4% | – | +17.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -117.8% | 1.6% | -1.3% | |
| Return on assets | -67.8% | 1.2% | -1.1% | |
| Current ratio | 4.08 | 7.37 | 5.94 | |
| Debt to equity | – | 0.01 | 0.01 | |
| Net debt to EBITDA | – | 21.19× | 1.95× | |
| Interest coverage | -48.5× | – | – | |
| Inventory turnover | 1.9× | – | 1.2× | |
| Capex to revenue | 1.7% | 4.1% | 9.9% | |
| Diluted shares | 13M | 27M | 49M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Biolife Solutions generated $54.13M from operations and spent $37.86M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$54.13M
Used
$37.86M
Capital expenditure$37.86M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4.8%
×Asset turnover0.24×
×Equity multiplier1.12×
=Return on equity, FY2025-1.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4.8% | 0.24× | 1.12× | -1.3% |
| FY2024 | -27.0% | 0.18× | 1.18× | -5.9% |
| FY2023 | -100.0% | 0.16× | 1.23× | -19.4% |
| FY2022 | -183.4% | 0.15× | 1.19× | -33.2% |
| FY2021 | -7.5% | 0.30× | 1.16× | -2.6% |
| FY2020 | 4.1% | 0.29× | 1.32× | 1.6% |
| FY2019 | -6.1% | 0.40× | 2.39× | -5.7% |
| FY2018 | -126.7% | 0.69× | 11.30× | -980.6% |
| FY2017 | -22.8% | 1.10× | -3.15× | 79.0% |
| FY2016 | -83.6% | 0.81× | 1.74× | -117.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$4.60M
- Cash generatingOperating cash flow above zero$20.12M
- Return on assets improvedROA up on the prior year-4.9% → -1.2%
- Earnings backed by cashOperating cash flow above net income$20.12M vs -$4.60M
- Less leverageLong-term debt to assets fell1.3% → 0.0%
- Better liquidityCurrent ratio rose4.54 → 5.94
- No dilutionShare count did not rise46M → 49M
- Gross margin improvedGross margin up on the prior year67.11% → 64.56%
- More efficientAsset turnover rose0.18 → 0.24